ImmuneOncia is also positioning IMC-001 as the best-in-class anti-PD-L1. “Although current PD-1 ... has been shown to inhibit tumor growth in mouse xenograft models. IMC-002 is a fully human ...
Hosted on MSN1mon
Scientists unveil surprising human vs. mouse differences in a major cancer immunotherapy targetFurthering their analysis, the researchers tested the impact of PD-1 humanization in mice—replacing mouse PD-1 with the ... assess the impact of PD-1 on the anti-tumor activity of T cells ...
Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback